Literature DB >> 18006033

Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.

Timothy Dudek1, Lydia C Mathews, David M Knipe.   

Abstract

The herpes simplex virus 2 dl5-29 replication-defective mutant virus has been shown to induce protective immunity in mice and both prophylactic and therapeutic immunity in guinea pigs. In an attempt to improve the efficacy of dl5-29 we disrupted its U(L)41 gene, producing the triple mutant virus dl5-29-41L. dl5-29-41L has a decreased ability to inhibit host cell protein synthesis and a reduced cytopathic effect on cultured cells. When used to immunize mice, dl5-29-41L elicited significantly stronger neutralizing antibody responses and significantly stronger CD4(+) and CD8(+) cellular immune responses than dl5-29. The enhanced immune responses corresponded with increased protective capacity in a murine model of genital herpes. The protective immunity elicited by either virus was very durable, protecting mice for at least 7 months. Furthermore, we show that cell lysate preparations of both viruses were significantly more efficacious than the corresponding extracellular virus preparations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006033      PMCID: PMC2323115          DOI: 10.1016/j.virol.2007.10.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  48 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

3.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Granzyme A, a noncytolytic component of CD8(+) cell granules, restricts the spread of herpes simplex virus in the peripheral nervous systems of experimentally infected mice.

Authors:  R A Pereira; M M Simon; A Simmons
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Modification of primary and recurrent genital herpes in guinea pigs by passive immunization.

Authors:  Nigel Bourne; Richard B Pyles; David I Bernstein; Lawrence R Stanberry
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

6.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

7.  Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.

Authors:  B J Geiss; T J Smith; D A Leib; L A Morrison
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; B N Carriere; R L Hendricks
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection.

Authors:  Khuong B Nguyen; Wendy T Watford; Rachelle Salomon; Sigrun R Hofmann; Gary C Pien; Akio Morinobu; Massimo Gadina; John J O'Shea; Christine A Biron
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

10.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

View more
  20 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

3.  Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Authors:  Timothy E Dudek; Ernesto Torres-Lopez; Clyde Crumpacker; David M Knipe
Journal:  J Infect Dis       Date:  2011-04-14       Impact factor: 5.226

Review 4.  Recent advances in vaccine development for herpes simplex virus types I and II.

Authors:  Jeffrey L Coleman; Deepak Shukla
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

Review 5.  Generating protective immunity against genital herpes.

Authors:  Haina Shin; Akiko Iwasaki
Journal:  Trends Immunol       Date:  2013-09-03       Impact factor: 16.687

6.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

7.  Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.

Authors:  Natalia J Reszka; Timothy Dudek; David M Knipe
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

8.  Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.

Authors:  Fernando Diaz; Sean Gregory; Hiroshi Nakashima; Mariano S Viapiano; David M Knipe
Journal:  Virology       Date:  2017-10-22       Impact factor: 3.616

9.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

10.  Genetic engineering of a modified herpes simplex virus 1 vaccine vector.

Authors:  Xueqiao Liu; Eeva Broberg; Daisuke Watanabe; Timothy Dudek; Neal Deluca; David M Knipe
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.